Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KDM1A | O60341 | 7/20 | 0.52 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | AKT1 | P31749 | 4/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2762498 | 0.81 | KDM1A (0.63) | GAAKDM1AMAOAMEN1KMT2A | |
| SCHEMBL2763141 | 0.81 | NPSR1 (0.57) | GAAKDM1AMAOAMEN1KMT2A | |
| SCHEMBL2762877 | 0.81 | MEN1 (0.72) | KDM1AMAOAMEN1KMT2ANPSR1 | |
| SCHEMBL2763143 | 0.81 | KDM1A (0.72) | KDM1AMAOAMEN1KMT2ANPSR1 | |
| SCHEMBL2762549 | 0.78 | RORC (0.51) | GAAKDM1AMAOAMEN1KMT2A | |
| SCHEMBL2762866 | 0.77 | MEN1 (0.57) | GAANPC1ALDH1A1RAB9AKDM1A | |
| SCHEMBL2762943 | 0.77 | KDM1A (0.72) | GAANPC1ALDH1A1RAB9AKDM1A | |
| SCHEMBL2762617 | 0.76 | KDM1A (0.56) | KDM1AMAOAMEN1KMT2A | |
| SCHEMBL2762303 | 0.74 | NPSR1 (0.57) | NPC1ALDH1A1RAB9AKDM1AMAOA | |
| SCHEMBL2763159 | 0.74 | MAPT (0.71) | GAANPC1ALDH1A1RAB9AKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7132436-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2006-11-07 | — | — | US | claimed |
| WO-2004112783-A1 | NEW USE IV | BIOVITRUM AB (SE) | 2004-12-29 | — | — | WO | claimed |
| US-20030166689-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | CLARIO TECH LIMITED (GB) | 2003-09-04 | — | — | US | claimed |
| CN-1437588-A | 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors | BIOVITRUM AB (SE) | 2003-08-20 | — | — | CN | claimed |
| EP-1283832-B1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2010-10-20 | — | — | EP | disclosed |
| US-7132436-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2006-11-07 | — | — | US | disclosed |
| US-20030166689-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | CLARIO TECH LIMITED (GB) | 2003-09-04 | — | — | US | disclosed |
| CN-1437588-A | 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors | BIOVITRUM AB (SE) | 2003-08-20 | — | — | CN | disclosed |
| EP-1283832-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2003-02-19 | — | — | EP | disclosed |
| WO-2001090092-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166689-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD11B2 | GAA 373/4885NPC1 443/4885ALDH1A1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.